Hummingbird Bioscience Pte. Ltd., of Singapore, said it completed an extended series A financing round led by Heritas Capital Management and SEEDS Capital, the investment arm of Enterprise Singapore. Hummingbird's existing investors, including Decheng Capital, which led the series A financing round, also participated. 

Recce Pharmaceuticals Ltd., of Sydney, appointed John Prendergast independent chair of its board, Graham Melrose executive director and chief research officer and Justin Ward executive director of its board. 

Researchers have shown that by using a combination of genome editing and long-acting slow-effective release antiviral therapy (LASER ART), they were able to eradicate HIV reservoirs and cure nearly 40% of HIV-infected mice.

Prestige Biopharma Pte. Ltd., of Singapore, and Moscow, Russia-based Pharmapark LLC said they entered a binding agreement for the exclusive partnership and supply for the commercialization of Prestige's trastuzumab biosimilar in the Russian Federation.

PERTH, Australia – Adelaide, Australia-based Bionomics Inc. reported another trial failure with its lead compound, BNC-210, in elderly patients with agitation, but it is still clinging on to hopes that the compound will show a clinical benefit for post-traumatic stress disorder (PTSD).

HONG KONG – To improve public health care in Brazil, Bioneer Corp., a South Korean biotech, and Brazilian government-run Institute of Technology on Imunobiologicals (Bio-Manguinhos) will focus on business development and R&D of in vitro diagnostics and new drugs.

HONG KONG – Incyte Corp. entered a collaboration and licensing deal to flip its greater China rights to an investigational anti-PD-1 monoclonal antibody to Zai Lab Ltd., of Shanghai. The candidate, INCMGA-0012, is currently being evaluated as a monotherapy in registration-directed trials for patients with MSI-high endometrial cancer, Merkel cell carcinoma and anal cancer.